The Food and Drug Administration hereby notifies the general public of the suspension of the FDA Customer Relation Management Information System (FDA-CRMIS) which was implemented through the issuance of FDA Advisory No. 2023-1881 dated 14 August 2023.
The FDA-CRMIS shall be suspended from 01 March 2024 until further notice from the FDA.
All received complaints, feedback, and inquiries in the CRMIS prior to this advisory shall be processed accordingly.
For everyone’s information and guidance.